Wasatch Advisors Inc Esperion Therapeutics, Inc. Transaction History
Wasatch Advisors Inc
- $17.6 Billion
- Q1 2025
A detailed history of Wasatch Advisors Inc transactions in Esperion Therapeutics, Inc. stock. As of the latest transaction made, Wasatch Advisors Inc holds 10,931,257 shares of ESPR stock, worth $12.8 Million. This represents 0.09% of its overall portfolio holdings.
Number of Shares
10,931,257
Previous 24,482,258
55.35%
Holding current value
$12.8 Million
Previous $53.9 Million
70.77%
% of portfolio
0.09%
Previous 0.27%
Shares
32 transactions
Others Institutions Holding ESPR
# of Institutions
200Shares Held
119MCall Options Held
171KPut Options Held
679K-
Black Rock Inc. New York, NY14MShares$16.4 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA11.5MShares$13.4 Million0.0% of portfolio
-
Bellevue Group Ag Kuesnacht, V89.69MShares$11.3 Million0.32% of portfolio
-
Two Seas Capital LP Rye, NY6.93MShares$8.11 Million0.36% of portfolio
-
Morgan Stanley New York, NY6.59MShares$7.71 Million0.0% of portfolio
About Esperion Therapeutics, Inc.
- Ticker ESPR
- Exchange NASDAQ
- Sector Healthcare
- Industry Drug Manufacturers—Specialty & Generic
- Shares Outstandng 66,551,600
- Market Cap $77.9M
- Description
- Esperion Therapeutics, Inc., a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol. Its lead product candidates are NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets for the treatment of patients with atherosclerotic cardiovascul...